NLRP3/NALP3 Antibody Blocking Peptide
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-77080PEP
Key Product Details
Conjugate
Unconjugated
Applications
Antibody Competition
Product Specifications
Description
A NLRP3/NALP3 antibody blocking peptide.
Application Notes
This peptide is useful as a blocking peptide for NBP1-77080. For further blocking peptide related protocol, click here.
Protein / Peptide Type
Antibody Blocking Peptide
Scientific Data Images for NLRP3/NALP3 Antibody Blocking Peptide
Western Blot: NLRP3/NALP3 Antibody Blocking Peptide [NBP1-77080PEP]
Western Blot: NALP3 Peptide [NBP1-77080PEP] - blocks the antibody activity completely in Western blot by incubating the peptide with equal volume of antibody for 30 min at 37C.Formulation, Preparation and Storage
NBP1-77080PEP
Formulation | diH2O |
Preservative | 0.02% Sodium Azide |
Concentration | 1.0 mg/ml |
Shipping | The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage | Store at -20C. Avoid freeze-thaw cycles. |
Background: NLRP3/NALP3
NLRP3 is expressed in a variety of cell types such as monocytes, dendritic cells, lymphocytes and epithelial cells (3). Abnormal NLRP3 activation may occur as the result of inherited mutations and is associated with diseases such as hereditary periodic fevers (HPFs) and familial cold autoinflammatory syndrome (FCAS). Additionally, abnormal NLRP3 activation is associated with a variety of diseases such as gout, obesity, atherosclerosis, Alzheimers, multiple sclerosis and type 2 diabetes (1, 3). NLRP3 inflammasome is regulated by several post-translational modifications (e.g., ubiquitination, phosphorylation and sumoylation) as well as by various interacting proteins (e.g., JNK1, FBXO3, TXNIP, MARK4 and PKD) (4).
References
1. Abderrazak, A., Syrovets, T., Couchie, D., El Hadri, K., Friguet, B., Simmet, T., & Rouis, M. (2015). NLRP3 inflammasome: From a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. Redox Biology. https://doi.org/10.1016/j.redox.2015.01.008
2. Yang, Y., Wang, H., Kouadir, M., Song, H., & Shi, F. (2019). Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death and Disease. https://doi.org/10.1038/s41419-019-1413-8
3. Zahid, A., Li, B., Kombe, A. J. K., Jin, T., & Tao, J. (2019). Pharmacological inhibitors of the nlrp3 inflammasome. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2019.02538
4. Kelley, N., Jeltema, D., Duan, Y., & He, Y. (2019). The NLRP3 inflammasome: An overview of mechanisms of activation and regulation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms20133328
Long Name
NLR Family, Pyrin Domain Containing 2
Alternate Names
AGTAVPRL, AII, CIAS1, Cryopyrin, FCAS, FCU, MWS, NACHT, NALP3, PYPAF1
Gene Symbol
NLRP3
Additional NLRP3/NALP3 Products
Product Documents for NLRP3/NALP3 Antibody Blocking Peptide
Product Specific Notices for NLRP3/NALP3 Antibody Blocking Peptide
This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...